AM Best to Attend Central American Congress of Insurers

MEXICO CITY--(BUSINESS WIRE)-- AM Best will attend the 30th Central American Congress of Insurers, which will take place Sept. 20–23, 2026, in San Pedro Sula, Honduras.

Carlos De la Torre, managing director of operations of AM Best’s Mexico-based subsidiary, will be on hand and available for meetings. De la Torre, who joined AM Best in 2018, has more than two decades of experience in the insurance and reinsurance industries, predominantly in Latin America. To set up a meeting, email [email protected]. AM Best maintains over 120 ratings on insurance companies in more than 20 Latin America and Caribbean countries.

The Central American Congress of Insurers event is hosted by Cámara Hondureña de Aseguradores (CAHDA), a nonprofit organization that brings together insurers that are authorized to operate in Honduras.

To learn more about the event, which will be held at the Copantl Hotel & Convention Center, visit here.

AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

Copyright © 2026 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260909704182/en/

Christopher Sharkey
Associate Director, Public Relations
+1 908 882 2310
[email protected]

Al Slavin
Senior Public Relations Specialist
+1 908 882 2318
[email protected]

Source: AM Best

You May Also Be Interested In

• Plastics Recycling: TotalEnergies Becomes the Sole Owner of the Grandpuits Advanced Plastics Recycling Plant
• Munters completes expansion of data center cooling campus in Daleville, Virginia
• The U.S. FDA grants orphan drug designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for treatment of endogenous Cushing's syndrome